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Abstract (241 words) 
 
Objective We related organ-specific autoantibodies, including diabetes-associated antibodies 
(DAA) and non-diabetes-associated autoantibodies (non-DAA) to systemic cytokines/ 
chemokines in type 1 and type 2 diabetes.  
Research Design and Methods From the European Action LADA cohort, patients with 
adult-onset type 1 diabetes (n=80, of which 50 had LADA and 30 had classic type 1 diabetes) 
and type 2 diabetes (n=626) were analysed for DAA (GADA, IA2A, ICA, ZnT8A), non-DAA 
(TGA, TPOA, PCA) and 10 immune mediator concentrations (measured by LUMINEX).  
Results Type 1 diabetes patients (whether classic type 1 diabetes or LADA), apart from their 
clinical phenotype, could not be distinguished by either autoantibodies (both DAA and non-
DAA) or immune mediators. In type 1 diabetes most immune mediators (9/10) were 
negatively correlated with DAA titres. Type 2 diabetes patients, by definition without DAA, 
had fewer non-DAA (p<0.0005), but higher levels of pro-inflammatory immune mediators, 
especially compared with type 1 diabetes patients with high GADA titre; IL-6 (p<0.001), sE-
Selectin (p<0.01) and IL-1Ra (p=0.052, trend). 
Conclusions Patients with type 1 diabetes had more DAA and non-DAA than type 2 diabetes, 
while the frequency and nature of these autoantibodies was broadly similar in classic type 1 
diabetes and LADA. Systemic immune mediator levels, in the main, were negatively 
correlated with DAA titres, and, for some, higher in type 2 diabetes, especially when 
compared with high titre GADA patients. Differences in the clinical classification of diabetes 
are associated with graded differences in adaptive and innate immune reactivity.     
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Introduction  
The definition of type 1 diabetes is clinically exclusive, encompassing patients with diabetes-
associated autoantibodies (DAA) plus, when diagnosed outside a surveillance program, 
insulin dependence. Difficulty arises when patients with non-insulin requiring diabetes, 
clinically like type 2 diabetes, have immuno-genetic characteristics of type 1 diabetes. Such 
patients have been designated latent autoimmune diabetes in adults (LADA), also called 
slowly progressive insulin-dependent diabetes (SPIDDM) or type 1.5 diabetes (1). Adult-
onset autoimmune type 1 diabetes (AID) is characterized by diabetes associated antibodies 
(DAA), usually autoantibodies against glutamic acid decarboxylase (GADA) (1,2) and 
encompasses patients with both classic type 1 diabetes, and LADA, of which the latter is most 
prevalent (2). Despite having different clinical presentations and phenotype, adults with 
classic type 1 diabetes and LADA resemble each other as regards their HLA and non-HLA 
genetic risk, the presence of DAA - predominantly GADA, the frequency of thyroid peroxides 
autoantibodies (TPOA), frequency of metabolic syndrome and levels in peripheral blood of 
systemic cytokines (IL-6, TNF-α, IL-1Ra, IL-10), chemokines (CCL2, CCL3, CCL4), 
adhesion molecules (sE-Selectin, sICAM-1 and sVCAM-1) and peripheral B-lymphocyte 
subsets (2-8). In contrast, patients with type 2 diabetes do not have an HLA genetic 
association, do not have DAA (1-4), have low frequency of TPOA (9) and substantially 
higher frequency of metabolic syndrome (10). Similarly, some systemic serum immune 
mediators are higher in type 2 diabetes than in type 1 diabetes including LADA, e.g. systemic 
cytokines (IL-6, TNF-α, IL-1Ra, IL-10), chemokines (CCL2, CCL3, CCL4) and adhesion 
molecules (sE-Selectin, sICAM-1 and sVCAM-1) (11,12).  
In previous studies we defined a non-random association in type 1 diabetes between adaptive 
immune changes (the presence and number of DAA) and innate immune changes (the serum 
levels of systemic cytokines and chemokines) (11-15). Here, we extend and expand these 
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studies to include a range of adult-onset clinical diabetes (both forms of type 1 diabetes as 
well as type 2 diabetes, each analysed for both DAA and non-DAA antibodies as well as a 
panel of systemic immune mediators: classic type 1 diabetes cytokines, chemokines and 
adhesion molecules. Our hypothesis is that innate (immune mediators) and adaptive immune 
reactivity (antibodies) can occur in both the major types of diabetes; adult-onset type 1 
diabetes is predominantly associated with adaptive immune changes, while type 2 diabetes is 
predominantly associated with innate immune changes.  Here we show graded differences in 
adaptive and innate immune changes across the classification of diabetes.    
  
7 
 
 
Research Design and Methods 
 
Patients The Action LADA multicentre study was performed to identify immune and clinical 
risk factors for adult-onset autoimmune diabetes (AID), including its epidemiology, genetic 
susceptibility, metabolic characteristics and clinical progression (16). The study population 
for the present study consisted of 706 individuals aged from 30 to 70 years; all had been 
diagnosed with diabetes within 5 years before entering this cross-sectional study from the 
Action LADA cohort (2). The cohort consisted of 50 subjects with LADA, 30 with type 1 
diabetes and 626 subjects with type 2 diabetes. Patients with other diabetes forms were 
excluded.  
Serum samples were randomly selected with stratification for age and significant serum 
samples left for analysis. Patients with classic type 1 diabetes were DAA-positive and 
received insulin treatment shortly after diabetes diagnosis. GADA-positive patients aged from 
30 to 70 years who did not use insulin treatment for at least 6 months after diagnosis were 
termed LADA. The focus of anti-hyperglycaemic medication was on insulin, as the time to 
start of insulin treatment contributed to the definition of LADA. Antidiabetic medications, 
other than insulin, were not evaluated. GADA negative and other DAA negative patients who 
did not use insulin at least for the first year after diagnosis were defined as having type 2 
diabetes.  
Blood withdrawal from all participants was carried out in the fasting state. The local ethics 
committees of each study centre approved the study protocol, in accordance with the 
Declaration of Helsinki. All patients gave written informed consent for the study. 
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Antibody measurements DAA directed against islets (islet cell antibodies, ICA) (13), 
glutamic acid decarboxylase (GADA), insulinoma-associated antigen (IA2A) and zinc 
transporter T8 (ZnT8A) were determined (2).  
Non-DAA directed against transglutaminase (TGA), parietal cells (PCA) and thyroid (TPOA) 
were measured as described. We chose to measure TPOA, PCA and TGA as they are known 
to be frequently positive in patients with autoimmune diabetes and are well-established gold 
standards to detect autoimmunity against thyroid, parietal cells and intestinal villous epithelial 
cells (17-21).  
In brief, TPOA were examined by B.R.A.H.M.S TPO-Ab RIA (B.R.A.H.M.S. AG) using 
native thyroid peroxidase as antigen, with results expressed in AU/ml. h and the functional 
assay sensitivity as 14 AU/ml; the upper limit of detection is 15,000 AU/ml, cut-off for 
positivity was 60 AU/ml.  
Gastric H+/K+-ATPase IgG autoantibodies (PCA) were determined by ELISA (Euroimmun 
AG; Lübeck, Germany) according to the manufacturer´s instructions (cut-off 20 AU/ml).  
Tissue transglutaminase antibodies (TGA) were measured by IgA-ELISA (Euroimmun AG); 
assay has an upper limit of detection of 200/AU/ml and a cut-off of 20 AU/ml. The intra- and 
inter-assay variation was 3.5% and 6.8%, respectively. 
 
Systemic cytokines and chemokines Soluble immune mediators were measured as described 
(11, 12). Serum samples were obtained in a standardized form from freshly drawn blood 
samples from fasting subjects in the morning hours, and were stored at -80°C until the time of 
the assay without prior thawing. In brief, serum concentrations for sICAM-1, sVCAM-1, sE-
Selectin, CCL2, CCL3 and CCL4 were determined with commercially available multiplex-
bead technology kits (Fluorokine MAP; R&D Systems, Wiesbaden, Germany). Intra- and 
inter-assay coefficients of variations were <5% and <11%, respectively.  
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The detection limits of the assays were 13.8 ng/ml for sICAM-1, 69.0 ng/ml for sVCAM-1, 
17.1 ng/ml for sE-Selectin, 40.3 pg/ml for CCL2, 2.4 pg/ml for CCL3 and 0.4 pg/ml for 
CCL4. At least 95% of serum concentrations were above the detection limit for all markers 
except for CCL3 levels, which were detectable in 72% of all samples. Determinations of 
immune mediators concentrations lower than the detection limit were assigned a value half of 
the detection limit as described (11, 22). 
Serum cytokine concentrations of IL-1Ra, IL-6, TNF-α and IL-10 were measured by 
multiplex-bead technology using commercially available kits (Fluorokine MAP; R&D 
Systems, Wiesbaden, Germany). The detection limits of the assays were 9.56 pg/ml for IL-
1RA, 0.1 pg/ml for IL-6, 0.08 pg/ml for TNF-α and 0.25 pg/ml for IL-10. For cytokine 
concentrations lower than the detection limit a value half of the detection limit was assigned 
(IL-6, n=46; IL-1Ra, n=0; TNF-α, n=0). Concentration of cytokine IL-10 was only detectable 
in 44% of the samples. Immunoassays showed inter-assay variations < 20% and intra-assay 
variations < 10%.  
 
Statistical methods We performed the analyses in randomly selected serum samples from 
participants of Action LADA that were stratified by age. Analyses were performed using SAS 
Enterprise Guide version 4.2 (SAS Institute, Cary, NC, USA) and GraphPad Prism version 4 
for Windows (GraphPad Software, La Jolla, California, USA). Continuous variables are 
presented as medians and range if not indicated otherwise. First, Gaussian distribution of data 
was assessed using the Kolmogorov–Smirnov test. The Kruskal–Wallis and Mann–Whitney 
tests were used to compare continuous variables. Fisher’s exact test or the χ2 test was 
performed to evaluate the differences in categorical data with two or more classes. Tests were 
not adjusted for multiple comparisons and are therefore descriptive if not indicated otherwise. 
Univariate correlations between organ specific antibodies titers, sex (men=1, women= 2), age, 
10 
 
 
BMI and diabetes duration were described by Spearman correlation (R). Kruskal-Wallis test 
was performed for the association analysis between systemic cytokines and multiple positivity 
for DAA and non-DAA. Associations of antibodies with cytokines upon adjustments for 
confounders including sex, age, BMI, and diabetes duration were carried out with multivariate 
regression analysis.  
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Results  
 
Patients characteristics As expected adult onset autoimmune diabetes (AID) patients, 
including classic adult onset type 1 diabetes and LADA, and type 2 diabetes patients differed 
by age (p <0.0001), BMI (p <0.0001), diabetes duration (p <0.0001) and family history for 
diabetes (p <0.01). Classic type 1 diabetes patients were the youngest (median age 44.65 
years), type 2 diabetes patients had the highest BMI (30.13 kg/m2), and LADA cases had the 
longest diabetes duration (2.92 years) (Table 1).  
 
Diabetes- Associated Antibodies Adult onset autoimmune diabetes type 1 diabetes patients 
(n=80) had by definition, one or more DAA (GADA, IA2A, ZnT8A, ICA) and within that 
group LADA (n=50) were, by definition, at least positive for GADA and did not start insulin 
therapy for at least 6 months post-diagnosis. Of classic type 1 diabetes patients, started on 
insulin close to diagnosis (n=30), 93.3% were GADA positive and their type of DAA did not 
differ from LADA cases (Table 1). Type 2 diabetes patients were, by definition, negative for 
DAA. Of all autoimmune diabetes patients (n=80), 30 (37.5%) were also positive for ICA, 16 
had IA2A (20%) and 10 had ZnT8A (12.5%) (Table 1). Of adult onset autoimmune diabetes 
patients (n=80) only 5 had all four DAA (6.25%); 8 (10%) had three DAA and 23 (28.75%) 
had two DAA and 44 (55%) were single DAA positive (Suppl. table 1). Classic type 1 
diabetes did not significantly differ from LADA in this comparison. Similarly, DAA titres did 
not differ among type 1 diabetes patients including LADA (data not shown). In adult onset 
autoimmune diabetes patients (n=80), 54 had high GADA titres, that is > 200 WHO Units as 
defined by an inflection point in signal from the cohort previously described (2), and the 
remainder (n=26) were designated low GADA titres < 200 WHO Units. High GADA titre 
patients compared with low GADA titre patients did not differ in terms of the number of 
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DAA or non-DAA (data not shown), nor were the groups with high versus low GADA titres 
clinically different, including age, BMI and diabetes duration (data not shown).  
 
Non-Diabetes Associated Autoantibodies   
Non-Diabetes Associated Autoantibodies Non-DAA were detected more often in patients 
with adult onset autoimmune diabetes, whether LADA (19/50, 38%) or classic type 1 diabetes 
(15/30, 50%), when compared with type 2 diabetes (145/626, 23.2%) (p= 0.0004). TPOA 
were more frequent in adult onset autoimmune diabetes (26/80, 32.5%) than in type 2 diabetes 
(85/626 13.58%) (p<0.0001); while their frequency in LADA (15/50, 30%) did not differ 
from classic type 1 diabetes (11/30, 36.67%) (p=0.538) (Table 1). Positivity for both TPOA 
and PCA was marginally greater in adult onset autoimmune diabetes, both classic type 1 
diabetes (3/30, 10%) and LADA (4/50; 8%), compared to type 2 diabetes patients (18/626 
2.9%) (p=0.024). The clinical groups did not differ for TGA positivity or PCA positivity 
(Table 1). PCA outlier (defined as PCA >80 AU/ml) do associate with positive TPOA in 
LADA in 4 out 5 cases, but not in type 2 diabetesor type 1 diabetes. TGA outlier (defined as 
TGA > 30 AU/ml) did not correspond with other non-DAA (PCA and TPOA). TPOA outlier 
(defined as TPOA >300 AU/ml) associated with positive PCA in 1 out of 5 classic type 1 
diabetes and in 4 out of 18 cases in type 2 diabetes. Overall, outliers of one non-DAA were 
not significantly associated with other non-DAA except for PCA and TPOA in LADA cases. 
Non-Diabetes Associated Autoantibodies titres Among adult onset autoimmune diabetes 
patients, high and low titre GADA were not associated with either their classification as 
classic type 1 diabetes or LADA, the number or titre of non-DAA (data not shown) nor did 
TPOA, TGA or PCA titres differ between LADA and classic type 1 diabetes (Figure 1). In 
comparison with type 2 diabetes, adult onset autoimmune diabetes patients had lower mean 
TGA titres (Kruskal Wallis p=0.003, post hoc Dunn’s comparison p< 0.05), while mean 
13 
 
 
TPOA titres in classic type 1 diabetes patients were higher (Kruskal Wallis p= 0.008, post hoc 
Dunn’s comparison p< 0.05, Figure 1).  
  
Association of DAA and non-DAA with clinical demographics There was no significant 
relationship between DAA concentrations and either sex, age, BMI or diabetes duration, with 
the exception that ZnT8A titres correlated positively with BMI (p=0.001, r= 0.548) in classic 
type 1 diabetes patients. Statistically significant associations were detected for non-DAA but 
did not impact our conclusions (Suppl. table 2). More specifically, sex was significantly 
related to PCA in type 1 diabetes in that PCA titres were increased in male, age was positively 
associated with PCA in LADA (r=0.29, p=0.038) and type 2 diabetes patients (r=0.15, p= 
0.003). Age was negatively related with TPOA (r=-0.17, p= 0.001). BMI was positively 
associated with PCA (r=0.374, p= 0.03). 
 
Associations of DAA and non-DAA with systemic immune-mediators  
First, we investigated associations of antibodies with immune-mediators without adjustment 
for demographic effects. In patients with adult onset autoimmune diabetes (AID, n=80), we 
detected significant associations of systemic immune mediators and antibody titres in 14 
combinations: 10 with DAA (9 negative, 1 positive) and 4 with non-DAA (TGA, TPOA) (2 
negative, 2 positive) (table 2). Interestingly, no significant association of GADA with immune 
mediators was observed in this analysis.   
As we detected some association of sex, age and BMI with non-DAA concentrations (Suppl. 
table 2), we adjusted for these parameters in further analysis. After adjustment for sex, age, 
BMI and diabetes duration, non-DAA associated significantly only for PCA and IL-10 
(p=0.001, negative correlation). Two DAA were negatively correlated with immune 
mediators upon adjustments: IA-2A and TNF-α (p=0.0278), ICA and sVCAM-1 (p=0.0065), 
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sICAM-1 (p= 0.011) and TNF-α (p= 0.011). ZnT8A titre was associated with IL-6 (p=0.004, 
positive correlation). That means, of the 14 combinations found in the unadjusted analysis, 5 
remained significant after adjustment and one association was newly significant (Table 2), 
most of them negatively correlated. 
In patients with type 2 diabetes (n=626), without adjustment for demographic effects, we 
detected six associations of systemic immune mediators and non-DAA titres: all of them 
negative (PCA with IL-1Ra (r= -0.148, p = 0.025); IL-6 (r= -0.146, p= 0.027); IL-10 (r= -
0.133, p= 0.044), and CCL2 (r= -0.133, p=0.043); TPOA with TNF-α (r= -0.157, p= 0.018) 
and sVCAM-1 (r= -0.198, 0.0026). TGA were excluded from these analyses, as so few 
patients were positive. After adjustment for sex, age, BMI and diabetes duration, non-DAA 
were not associated with any of the immune mediators in patients with type 2 diabetes 
(n=626). 
 
Association of high GADA titres with cytokines  
We compared adult onset autoimmune diabetes patients with high GADA (>200 U/ml), low 
GADA (<200 U/ml) and type 2 diabetes patients (all GADA negative). High titre GADA 
patients had lower IL-6 (p< 0.001), and sE-Selectin (p< 0.01) and a trend toward decreased 
IL-1Ra (p= 0.052), with a significant trend across the three diabetes cohorts for the former 
two (p<0.01) indicating an inverse association between an adaptive autoimmune response 
(GADA) and these systemic immune mediators (Figure 2). There were no significant 
differences for the other cytokines tested, including IL-10, TNF-α, CCL2, CCL3, CCL4, 
sICAM-1 and sVCAM-1. 
  
15 
 
 
Conclusions 
 
We explored the relationship within the two major types of diabetes between adaptive 
immunity, represented by both DAA and non-DAA, and innate immunity, represented by 10 
systemic immune mediators including cytokines, chemokines and adhesion molecules in the 
Action LADA cohort. It is well established that type 1 diabetes is associated with DAA 
irrespective of the clinical phenotype or age at diagnosis. In our study, neither DAA nor non-
DAA nor immune mediators could distinguish classic type 1 diabetes from LADA.  
As expected, we detected DAA in a large series of over 6,000 adult patients diagnosed with 
diabetes (2). We selected patients from that series with DAA based on their immediate need 
for insulin treatment (classic type 1 diabetes) and the lack of that need for at least six months 
(LADA) plus availability of sufficient sera from the same sample. The majority of these 
adult-onset cases had a single DAA and the dominant autoantibody was GADA. There was no 
difference in the frequency or titre of these DAA and the need for insulin therapy or initial 
clinical phenotype. Type 1 diabetes is associated with other autoimmune diseases including 
Pernicious Anaemia and Hashimoto’s thyroiditis, respectively characterized by parietal cell 
autoantibodies (PCA) and thyroid peroxidase autoantibodies (TPOA) (25). The increased 
frequency of TPOA and PCA are well described in type 1 diabetes but also in LADA patients, 
e.g. the Italian NIRAD study and the Chinese LADA study (9,26–28). As expected, the 
frequency of non-DAA here was increased in type 1 diabetes compared with patients with 
type 2 diabetes irrespective of the initial need for insulin treatment, that is in both classic type 
1 diabetes and in LADA; but that increase was due mainly to TPOA and to a lesser extent 
PCA but not to TGA. Whilst some non-DAA are a feature of type 1 diabetes, these 
autoantibodies, notably TPOA, were also found in a proportion of patients with type 2 
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diabetes. The percentage of non-DAA positive patients with LADA in our Action LADA 
cohort was similar to that from other cohorts (9, 28). 
 
Importantly and unique to this study, we found for autoimmune diabetes, that significantly 
altered immune mediator levels were nearly all (9/10) negatively correlated with DAA titres 
and two of four were negatively associated with non-DAA. Serum concentrations of some 
immune mediators i.e. a cytokine and an adhesion molecule, were overall slightly increased in 
type 2 diabetes compared to adult onset autoimmune diabetes patients with high GADA titre. 
There was a graded increase in IL-6 and sE-Selectin across the main types of diabetes, with 
levels being highest in type 2 diabetes patients and lowest in those patients with classic type 1 
diabetes, whilst LADA patients had intermediate levels without significant differences from 
classic type 1 diabetes. As in most studies, there was a considerable overlap of cytokine 
concentrations in classic type 1 diabetes, LADA and also type 2 diabetes and innate immune 
markers measured in serum are not sufficiently diagnostic to dissect out the different diabetes 
forms. This is not surprising as innate as well as adaptive immune alterations may have a role 
in all diabetes types including type 1 diabetes, LADA and type 2 diabetes (5-7,11,12,15,29). 
The amount of GADA titre was not associated with classic type 1 diabetes or LADA, and 
similarly, levels of the immune effector molecules were not different between these two 
clinically distinct forms of autoimmune diabetes and lower than in type 2 diabetes. It follows 
that there is an inverse relationship between adaptive immunity (antibodies, DAA, non-DAA) 
associated with type 1 diabetes and innate immune effector molecules (cytokines, 
chemokines, adhesion molecules) associated with type 2 diabetes, with a graded change 
across the clinical categories. Whether the observed inverse innate and adaptive immune 
responses are causal or merely associated cannot be addressed as our study was exploratory. 
However, one potential explanation for the inverse relationship between adaptive and innate 
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immune responses is that immune regulation of one component limits the potentially 
exaggerated, and, therefore harmful, response of the other component. Alternatively, since 
altered innate immune responses are common to both major types of diabetes but adaptive 
immune responses are a characteristic of only AID, it is the possible that their effect is 
additive and, therefore, the greater the adaptive immune effect the less the innate immune 
effect required to develop clinical disease. 
Numerous studies have demonstrated clinical heterogeneity in autoimmune diabetes, 
especially adult-onset diabetes such that some patients present with severe insulin-dependent 
diabetes but others present with non-insulin requiring diabetes (1). Yet both these forms of 
diabetes are characterised by the presence of DAA, usually GADA, associated with genetic 
susceptibility through common Histocompatibility Lymphocyte Antigen (HLA) haplotypes. 
This clinical spectrum extends into childhood-onset autoimmune type 1 diabetes in which 
insulin-dependent patients have the same DAA, though not predominantly GADA, with a 
stronger HLA genetic susceptibility. That clinical heterogeneity is also reflected in striking 
variation in insulin secretion, illustrated by C-peptide levels, across the types of diabetes. 
Recent large studies have confirmed that there can be substantial serum C-peptide in adult-
onset type 1 diabetes, suggesting that it is difficult to distinguish some forms of adult-onset 
type 1 diabetes from type 2 diabetes based on C-peptide alone (23,24). This present study 
confirms previous studies indicating that LADA and classic type 1 diabetes have, despite 
clinical differences, a similar cytokine profile with similar levels of serum IL-6 and sE-
Selectin, with each being lower than their corresponding levels in type 2 diabetes. We have 
now analysed for the first time that relationship in more detail and found that there was an 
inverse relationship between DAA titres and the levels of four immune mediator molecules 
such that high titres of one, e.g. ICA, were associated with lower levels of the other e.g. 
sVCAM-1, sICAM-1 and TNF-α. It is unclear what pathogenetic mechanism accounts for the 
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relationship between these effector molecules and the two major types of diabetes, but that 
inverse relationship is even detected within autoimmune diabetes; the group with highest 
GADA showed decreased IL-6 and sE-Selectin. It will require further study to define the 
reason for this inverse relationship between adaptive and innate immune changes across a 
range of adult-onset forms of diabetes.  
In summary, we present the first evidence for an effect in both adaptive and innate immunity 
across type 1 diabetes and type 2 diabetes. Since this graded effect was seen between type 1 
diabetes and type 2 diabetes, and even within autoimmune diabetes, the change in immune 
effectors likely reflects some common pathogenetic mechanism between the major types of 
the disease.  
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Figure legends 
Figure 1 
Levels of non-DAA PCA, TGA, TPOA, in type 2 diabetes, classic type 1 diabetes, LADA and 
adult onset autoimmune (AID, classic type 1 diabetes and LADA combined) . Cut-off for 
positivity was 20 AU/ml for PCA, 20 AU/ml for TGA, and 60 AU/ml for TPOA. Shown are 
all individual data and mean. p- values from Dunn's Multiple Comparison Test.   
 
Figure 2 
Concentrations (Box and whiskers) of cytokines, chemokines and soluble adhesion molecules 
in patients with adult autoimmune diabetes (AID) that were GADA high (>200 U/ml) or 
GADA low (<200 U/ml) and type 2 diabetes patients that were GADA negative. P-values 
from non-parametric Kruskal Wallis upper line, P-values from Dunn’s Multiple Comparison 
Test lower line.  
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LADA 
 
n=50 
 
Classic Type 1 
diabetes   
n=30 
 
Type 2 diabetes 
 
n=626 
 
p-value 
Demographic     
Sex m/f 25/25 17/13 361/265 n.s. 
Age [years]  52.28  
(31.87 – 69.10) 
44.65 
(33.56- 66.13) 
56.08  
(30.15 – 69.83) 
P<0.0001 
BMI [kg/m2] 25.96  
(18.12 – 48.78) 
23.83  
(16.44 –53.15) 
30.13  
(18.00 – 71.94) 
P<0.0001 
Diabetes 
duration [yrs] 
2.92  
(0.05 – 6.63) 
0.59 
(0.02 – 5.36) 
2.00  
(0.0 – 5.79) 
P<0.0001 
Fam. hist diab 
pos/neg (% pos) 
33/ 17  
(66%) 
9/21  
(30%) 
347/279  
(55.4%) 
P= 0.0065 
Antibody 
status 
DAA n (%) 
    
GADA  50  
(100%) 
28  
(93.33%) 
0 n.s. 
IA2A  9  
(18.0%) 
7  
(23.3%) 
0 n.s. 
ZnT8A  6  
(12%) 
4  
(13.33%) 
0 n.s. 
ICA  18  
(36.0%) 
12  
(40%) 
0 n.s. 
Non-DAA  
n (%) 
    
TPOA  15  
(30%) 
11  
(36.67%) 
85  
(13.58%) 
p< 0.0001 
n.s. 
PCA  6  
(12%) 
6  
(20%) 
75  
(11.98%) 
n.s. 
n.s. 
TGA  1  
(2%) 
1  
(3.3%) 
5  
(0.8%) 
n.s. 
n.s. 
TPOA and 
PCA  
4  
(8%) 
3  
(10%) 
18  
(2.9%) 
p=0.0245 
n.s. 
 
Table 1  
Characteristics of the patients with LADA, classic type 1 diabetes, and type 2 diabetes. Data 
are shown as median (range) and numbers n (%). DAA, diabetes associated antibodies. P-
values refer to the comparison of the three groups by non-parametric Kruskal Wallis testing or 
Fisher’s exact test, two sided. DAA antibody positivity was compared between LADA and 
classic type 1 diabetes. Non-DAA antibody positivity was compared between LADA, classic 
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type 1 diabetes and type 2 diabetes (Kruskal Wallis test, p upper line), and between classic 
type 1 diabetes and LADA (p lower line). n.s. not significant   
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AID (n=80) 
 Non-DAA* 
 
DAA 
             PCA  TPOA ICA IA2 ZnT8A GADA 
IL-1Ra 
 
r value -0.01 
p value 0.93 
 
 0.09 
0.36 
 
-0.092 
0.34 
 
-0.20 
0.03 
 
0.12 
0.34 
 
0.13 
0.30 
 
IL-6 r value 0.06 
p value 0.52 
 
 -0.01 
0.90 
 
0.03 
0.77 
 
 
-0.26 
0.006 
 
 
0.27* 
0.0314 
 
 
-0.05 
0.67 
 
 
IL-10 r value -0.05* 
p value  0.64 
 
 
 -0.02 
0.85 
 
 
0.14 
0.14 
 
 
0.08 
0.40 
 
 
-0.19 
0.14 
 
 
-0.20 
0.10 
 
 
CCL2 r value -0.04 
p value 0.69 
 
 
 0.06 
0.53 
 
 
0.14 
0.14 
 
 
-0.08 
0.43 
 
 
-0.14 
0.27 
 
 
0.07 
0.56 
 
 
CCL3 r value  0.01 
p value 0.90 
 
 
 0.43 
<.0001 
 
 
0.13 
0.16 
 
 
-0.09 
0.38 
 
 
0.08 
0.54 
 
 
0.02 
0.90 
 
 
CCL4 r value 0.037 
p value  0.71 
 
 
 0.12 
0.20 
 
 
-0.03 
0.72 
 
 
0.04 
0.65 
 
 
0.17 
0.17 
 
 
-0.02 
0.89 
 
 
TNF-α r value -0.13 
p value  0.17 
 
 
 -0.20 
0.04 
 
 
-0.38* 
<.0001 
 
 
-0.31* 
0.0009 
 
 
0.03 
0.81 
 
 
-0.02 
0.9 
 
 
sICAM-1 r value 0.10 
p value 0.28 
 
 
 -0.09 
0.33 
 
 
-0.34* 
0.0004 
 
 
-0.26 
0.007 
 
 
0.08 
0.54 
 
 
0.13 
0.32 
 
 
sVCAM-1 r value 0.05 
p value 0.61 
 
 
 -0.24 
0.01 
 
 
-0.34* 
0.0004 
 
 
-0.09 
0.35 
 
 
0.22 
0.08 
 
 
0.20 
0.10 
 
 
sE-Selectin r value 0.24 
p value 0.01 
 
 
 0.002 
0.98 
 
 
-0.20 
0.04 
 
 
-0.28 
0.003 
 
 
-0.11 
0.38 
 
 
0.07 
0.60 
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Table 2 
Correlation analysis of immune mediators and antibody titres in patients with autoimmune 
diabetes (AID, classic type 1 diabetes and LADA combined). Shown are r- and p- values from 
Spearman analysis. Significant correlations are in bold. TGA were not analysed as only 2 of 
80 AID patients were positive for TGA. * Significant association after adjustment for sex, 
age, BMI, diabetes duration.  
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type 1 diabetes and type 2 diabetes (Kruskal Wallis test, p upper line), and between classic 
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Table 2 
Correlation analysis of immune mediators and antibody titres in patients with autoimmune 
diabetes (AID, classic type 1 diabetes and LADA combined). Shown are r- and p- values from 
Spearman analysis. Significant correlations are in bold. TGA were not analysed as only 2 of 
80 AID patients were positive for TGA. * Significant association after adjustment for sex, 
age, BMI, diabetes duration.  


  
Positivity of islet 
directed 
antibodies  
 
LADA 
 
n=50 
 
Classic Type 1 
diabetes   
n=30 
 
AID  
 
n=80 
 
p-value 
Single ab 
positive 
28/50 
(56%) 
16/30 
(53.33%) 
44/80 
(55 %) 
n.s. 
Double ab 
positive 
14/50 
(28%) 
9/30 
(30%) 
23/80 
(28.75%) 
n.s. 
Triple ab 
positive  
5/50 
(10%) 
3/30 
(10%) 
8/80 
(10%) 
n.s. 
Quadruple ab 
positive 
3/50 
(6%) 
2/30 
(6.66%) 
5/80 
(6.25%) 
n.s. 
 
Supplement table 1 
Data show the number and percentage of patients who are positive for one, two, three or four 
of the islet directed antibodies measured. LADA and classic type 1 diabetes patients did not 
differ statistically. ab, antibody; n.s., non-significant  
 
 
  
Association with  
Sex 
LADA 
N=50 
Classic Type 1 diabetes 
N=30 
Type 2 diabetes 
N=626 
PCA r = 0.16, p= 0.24 r = - 0.47, p = 0.0056 r= 0.09, p = 0.07 
TPOA r = 0.127, p = 0.37 r = - 0.09, p = 0.62 r = 0.09, p = 0.07 
Age 
PCA r = 0.29, p =  0.038 r = -0.13, p = 0.49 r = 0.15, p = 0.0034 
TPOA r = 0.100, p = 0.49 r = 0.15, p = 0.39 r =-0.17, p = 0.0010 
BMI 
PCA r = - 0.03, p = 0.82 r = 0.374, p = 0.0318 r = - 0.006, p = 0.91 
TPOA r = 0.08, P = 0.56 p = 0.16, p = 0.37 r = -0.06, p = 0.23 
 
Supplement table 2  
Association of sex, age and BMI with non-DAA concentrations. Shown are Spearman 
correlation R and respective p-values for BMI and age. Correlation analysis with sex was 
performed applying χ2 test (R) analysis. Significant p-values in bold. P-values not corrected 
for multiple comparison. TGA were excluded from the analysis, as only very few patients 
were positive for TGA (1/50 LADA, 1/30 classic type 1 diabetes, 5/626 type 2 diabetes).  
